Our institute on the biomedical campus provides a physical hub that combines the strength of academia and business to accelerate the development of therapies. Our research teams focus on the development of human models of disease and the use of gene editing to better understand how diseases arise, and the application of artificial intelligence and quantum computing to interrogate large patient and human tissue-based datasets.

Our institute is the headquarters of the Milner Therapeutics Consortium, a partnership of nine Pharma companies and three academic Institutions. This consortium provides unique and diverse routes for our partners to engage with Cambridge academics and entrepreneurs. By creating innovative models of cross-sector collaboration, the Milner model provides a leading example internationally of how academic discoveries can move from the lab and into developmental pipelines that result in effective therapies.

We provide entrepreneurs with a comprehensive support system designed to facilitate the growth of entrepreneurial ventures from conception to realization. We offer incubation facilities for young companies, programmes in educational ideation, such as Bio-spark, entrepreneurship and skills development, and a founders community. We are the biomedical hub for Connect: Health Tech, and we work with other University organizations to create a wealth of resources and commercial support for academics seeking to put ideas into practice.